Shanghai Henlius Pharmaceutical Co., Ltd (HKG: 2696) reported RMB 1.29 billion (USD 189.4 million) in revenue for the 2022 interim period, a 103.5% year-on-year (YOY) increase. The growth was driven by sales of commercialized products and licensing income. R&D investment reached RMB 827.4 million (USD 121.5 million).
Product Pipeline
Henlius’s pipeline includes innovative and biosimilar drugs targeting oncology, autoimmune diseases, and eye diseases. The company has five products on the market in China, one approved overseas, and 13 new indications and four new marketing approvals under review.
Commercialized Products
- Rituximab (HanLiKang): Generated RMB 272.1 million (USD 40 million) in sales via a profit-sharing agreement with Fosun Pharma, plus RMB 9.3 million (USD 1.3 million) in licensing income. Approved in February 2022 for moderate to severe active rheumatoid arthritis (RA).
- Licensing Out: Signed deals with Getz Pharma, Eurofarma, and Abbott for biosimilars of adalimumab, rituximab, bevacizumab, and trastuzumab, covering 27 emerging markets. A major deal with Organon (NYSE: OGN) grants exclusive global commercialization rights (excluding Greater China) to HLX11 (pertuzumab) and HLX14 (denosumab), with an upfront payment of USD 73 million and total deal value of USD 541 million.
Pipeline Progress
- HLX11 (HER2 Antibody): Completed first patient dosing in Phase III trials.
- HLX14 (Denosumab Biosimilar): Approved for international multi-center Phase III study in Australia.
- HLX04-O (Anti-VEGF mAb): First dosed in international trials in Latvia and Australia, with approvals in China, the US, EU, and Singapore.
- Partnership: Collaborated with Palleon Pharmaceuticals to develop two bispecific antibodies-sialidase fusion proteins.-Fineline Info & Tech
